rucaparib camsylate · Pharmaand · NDA 209115
Rubraca
Earliest generic entry, as listed · earliest of 3 marketed strengths
17 Aug 2035
Blocked by patent: US 10130636, US 10130636, US 10130636, US 10130636, US 9987285.
Listed patents · 19 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10130636 | use U-2830 | 17 Aug 2035 |
| US 10130636 | use U-2273 | 17 Aug 2035 |
| US 10130636 | use U-2101 | 17 Aug 2035 |
| US 10130636 | use U-2012 | 17 Aug 2035 |
| US 9987285 | product | 17 Aug 2035 |
| US 8859562 | use U-2012 | 4 Aug 2031 |
| US 8859562 | use U-2273 | 4 Aug 2031 |
| US 8859562 | use U-2830 | 4 Aug 2031 |
| US 10278974 | product | 10 Feb 2031 |
| US 8754072 | substance, product | 10 Feb 2031 |
| US 9045487 | substance, product | 10 Feb 2031 |
| US 9861638 | use U-2273 | 10 Feb 2031 |
| US 9861638 | use U-2012 | 10 Feb 2031 |
| US 8071579 | use U-2012 | 12 Aug 2027 |
| US 8071579 | use U-2273 | 12 Aug 2027 |
| US 8071579 | use U-2830 | 12 Aug 2027 |
| US 8143241 | use U-2012 | 12 Aug 2027 |
| US 8143241 | use U-2830 | 12 Aug 2027 |
| US 8143241 | use U-2273 | 12 Aug 2027 |
Exclusivities · 1 unexpired
| I-982 | new indication (3 years) | 17 Dec 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209115 · 001 · RLD | tablet, oral | EQ 200MG BASE | 17 Aug 2035 |
| 209115 · 002 · RLD | tablet, oral | EQ 300MG BASE | 17 Aug 2035 |
| 209115 · 003 · RLD | tablet, oral | EQ 250MG BASE | 17 Aug 2035 |